Skip to Main Content

Advertisement

Skip Nav Destination

Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial

Blood Adv (2024) 8 (3): 802–814.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement